HIGH 8.4

CVE-2019-25718: Dräger Infinity Explorer C700 Kiosk Escape Privilege Escalation

The Dräger Infinity Explorer C700, a patient monitor interface device, contains a vulnerability that allows an attacker with local access to break out of its restricted kiosk environment and gain full control of the underlying operating system. Once escaped from kiosk mode, an attacker can manipulate the device's display, causing it to show incorrect patient data or no data at all—a serious concern in clinical settings where accurate vital sign monitoring is critical to patient safety.

Source data · NVD / CISA · public domain

CVSS
3.1 · 8.4 HIGH · CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
Weaknesses (CWE)
CWE-451
Affected products
2 configuration(s)
Published / Modified
2026-06-01 / 2026-06-30

NVD description (verbatim)

Dräger Infinity Explorer C700 contains a privilege escalation vulnerability that allows attackers to break out of kiosk mode and access the underlying operating system through a specific dialog interaction. Attackers can exploit this kiosk escape to take control of the operating system and cause the device to display incorrect or no information from the connected Delta Family patient monitor.

2 reference(s) · View on NVD →

SEC.co analysis · AI-assisted, reviewed against source

Technical summary

CVE-2019-25718 is a privilege escalation vulnerability in the Dräger Infinity Explorer C700 that exploits a flaw in dialog handling to achieve kiosk escape. The vulnerability exists in the device firmware and allows unauthenticated local attackers to bypass the restricted kiosk mode without requiring elevated privileges at the entry point. The attack vector is local (AV:L), requires no user interaction (UI:N), and grants the attacker complete confidentiality, integrity, and availability compromise (C:H/I:H/A:H). The issue is rooted in insufficient validation or insecure state management during specific dialog interactions, enabling unauthorized access to the underlying operating system.

Business impact

In healthcare environments, the Infinity Explorer C700 serves a critical role in patient monitoring workflows. Compromise of this device can result in: (1) Incorrect or absent vital sign data being displayed to clinical staff, potentially delaying or preventing appropriate medical intervention; (2) Loss of device availability during procedures, forcing manual fallback monitoring methods; (3) Reputational damage and regulatory scrutiny if patient safety is compromised; (4) Liability exposure if adverse patient outcomes are linked to device tampering. Organizations relying on these monitors for continuous care must treat this as a patient safety risk, not merely an IT security issue.

Affected systems

The vulnerability affects the Dräger Infinity Explorer C700 and its firmware. The Infinity Explorer C700 is typically deployed in hospital critical care units, operating rooms, and intensive care settings as a bedside patient monitor and data integration platform. If your organization uses Dräger Infinity Explorer C700 devices—particularly in clinical environments connected to Delta Family patient monitors—you should assume systems may be at risk until a vendor patch is verified and deployed.

Exploitability

Exploitation requires local access to the device, which limits the immediate risk in many settings but remains significant in healthcare environments where clinicians, maintenance staff, and potentially visitors may have physical proximity to monitoring equipment. The attack requires no special privileges to initiate (PR:N) and no user interaction (UI:N), meaning an attacker with physical access could execute the exploit in seconds without needing to social-engineer staff or obtain credentials. The specific dialog interaction pathway has not been disclosed in this advisory, so defenders cannot easily identify or block the vector without vendor guidance or device isolation. The vulnerability is not currently tracked in CISA's Known Exploited Vulnerabilities catalog, but local attack surface should not be underestimated in facilities with physical security gaps.

Remediation

Dräger must release a firmware patch that corrects the dialog handling logic and implements proper privilege boundary enforcement between kiosk mode and the underlying OS. Until such a patch is available and validated, organizations should implement compensating controls: (1) Restrict physical access to Infinity Explorer C700 devices using locked enclosures or secured mounting in areas with badge access; (2) Monitor device logs and console output for unexpected activity; (3) Ensure devices are isolated from untrusted networks and cannot be remotely accessed; (4) Consider temporary redundancy (secondary monitor or manual backup protocol) if the device is mission-critical; (5) Notify Dräger of your deployment and request expedited patch notification.

Patch guidance

Verify with Dräger support for the availability of a patched firmware version for your specific Infinity Explorer C700 model and software version. Given the publish date of June 2026, coordinate with Dräger's security response team to obtain the patch timeline and any interim mitigations. Apply patches during scheduled maintenance windows to avoid disruption to patient monitoring. Before deploying patches, validate compatibility with your Delta Family patient monitor integration to ensure no communication or data flow is affected. Document the pre-patch and post-patch firmware versions in your device management records for compliance and traceability.

Detection guidance

Monitor for unauthorized access to the underlying operating system on Infinity Explorer C700 devices. If device logs are accessible, look for evidence of privilege escalation events or unexpected process spawning outside the kiosk application. Check for unauthorized display changes (black screen, diagnostic output, or unexpected menus). Implement network monitoring to detect unusual outbound traffic from the device, as a compromised system may attempt to communicate with external systems. If your facility has any forensic tools or remote device management capabilities, perform spot checks on critical devices to verify the kiosk mode is intact and the display is showing valid patient data. Review physical access logs to the device area to correlate timing with any observed anomalies.

Why prioritize this

This vulnerability merits high priority (CVSS 8.4) due to the combination of high severity and direct threat to clinical operations. Although local access is required, healthcare environments often have looser physical security around bedside equipment compared to server rooms. The ability to alter or disable patient data display without requiring user interaction or credentials poses a direct patient safety risk. In regulated environments (hospitals, clinics), this may also trigger mandatory incident reporting obligations if exploited. Even the presence of an unpatched vulnerability can create compliance exposure during audits or investigations.

Risk score, explained

The CVSS 3.1 score of 8.4 (HIGH) reflects: local attack vector (no remote exploitation), low attack complexity, no privileges required at the starting point, no user interaction needed, and complete impact across confidentiality, integrity, and availability. The score does not account for the clinical context or the severity of displaying incorrect patient data; the numeric score reflects technical exploitability and system compromise. In a healthcare risk model, the business impact of this vulnerability may warrant even higher prioritization than the CVSS score suggests, because consequences extend beyond the IT system to patient outcomes.

Frequently asked questions

Can this vulnerability be exploited remotely?

No. The attack vector is local only (AV:L), meaning an attacker must have physical access to the Infinity Explorer C700 device or its network interface. Remote exploitation is not possible based on the technical details available. However, in healthcare networks, an attacker who gains network access to the device via an unsecured clinical network could potentially combine this vulnerability with other network-based attacks; isolation and network segmentation are recommended.

What happens if the kiosk is escaped? Can the attacker access patient data?

Once the kiosk is escaped, the attacker has full control of the underlying operating system (C:H/I:H/A:H). This means they can read, modify, or delete patient data stored or processed by the device, cause the monitor to display false information, disable the device entirely, or use it as a pivot point to other systems on the clinical network. The primary concern is the ability to corrupt or hide vital sign data, which poses direct patient safety risks.

Is there a workaround if I cannot patch immediately?

Complete workarounds are limited without the vendor patch. Mitigation strategies include: (1) restricting physical access to the device via locked enclosures or controlled-access areas; (2) deploying redundant monitoring devices so that loss of one monitor does not compromise patient safety; (3) monitoring device activity and display integrity during use; (4) ensuring the device is on an isolated clinical network without internet or untrusted connections; (5) requesting an expedited patch from Dräger support. These measures reduce risk but do not eliminate it.

Should this be reported to regulators or risk management?

Yes. In healthcare organizations, patient safety concerns must be escalated to clinical engineering, biomedical, and risk management teams immediately. Depending on your jurisdiction and regulatory obligations (FDA, Joint Commission, etc.), the vulnerability and any mitigation steps may require documentation or reporting. If the device is involved in a patient incident, the vulnerability context becomes even more critical. Consult your compliance and legal teams to determine notification requirements.

This analysis is provided for informational purposes and does not constitute professional medical, legal, or engineering advice. Organizations must verify all patch versions, timelines, and compatibility information directly with Dräger and their clinical engineering teams. Patient safety decisions and device deployment changes should involve clinical, biomedical, and regulatory stakeholders. SEC.co does not assume responsibility for the accuracy of vendor information or the outcomes of remediation actions. Always test patches in non-production environments before widespread deployment in clinical settings. Source: NVD (public-domain), retrieved 2026-07-07. Analysis generated by SEC.co (claude-haiku-4-5).